Life Sciences

China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
September 15, 2020
Stephen Ezell gave a presentation about the federal policies needed to turbocharge America’s biomanufacturing renaissance at the AURP BioHealth Caucus Conference on September 15, 2020.
September 15, 2020
America has successfully launched national innovation missions time and again.
September 8, 2020
China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.
August 13, 2020
Thirty-two state attorneys general have called for applying Bayh-Dole march-in rights on the only widely available therapeutic that has been FDA-approved for emergency use in treating coronavirus. They are wrong on both the facts and the law. As worryingly, their move threatens to undermine an effective environment for U.S. life-sciences innovation.
July 16, 2020
If the United States is serious about maintaining its leadership in biopharmaceuticals, then it’s time for policymakers to articulate and embrace a robust sectoral competitiveness strategy.
July 16, 2020
Marking the release of a new report, ITIF hosted a discussion with experts and leaders from leading biopharmaceutical startups to discuss current challenges and opportunities, and what the federal government should and should not do to maintain this unique American strength.
June 17, 2020
Stephen Ezell gave a presentation to the Technology Transfer Society of DC about the history of the Bayh-Dole Act and its contributions to America’s innovation system, particularly in the life-sciences sector.
June 15, 2020
COVID-19 has prompted calls for reshoring of medical goods, including strict “Buy American” prescriptions. While reshoring is important, “Buy American” fails to recognize the value of the global supply chain and avoids addressing the real problem, China.
May 27, 2020
In contrast to what critics might assert, now is not the time to undermine either the IP rights or reasonable pricing reimbursement approaches that have underpinned so much successful biomedical innovation, and which will be key to getting through this crisis.
May 15, 2020
The global community will only be able to overcome the coronavirus pandemic through intense collaboration, turbocharged innovation, and open trade, uninhibited by artificial barriers or restrictions—particularly when comes to medical supplies and research data.

Pages